Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 18:8:226.
doi: 10.3389/fonc.2018.00226. eCollection 2018.

Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors

Jens C Hahne  1 , Nicola Valeri  1   2
Affiliations
Review

Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors

Jens C Hahne et al. Front Oncol. .

Abstract

Non-coding RNAs are important regulators of gene expression and transcription. It is well established that impaired non-coding RNA expression especially the one of long non-coding RNAs and microRNAs is involved in a number of pathological conditions including cancer. Non-coding RNAs are responsible for the development of resistance to anticancer treatments as they regulate drug resistance-related genes, affect intracellular drug concentrations, induce alternative signaling pathways, alter drug efficiency via blocking cell cycle regulation, and DNA damage response. Furthermore, they can prevent therapeutic-induced cell death and promote epithelial-mesenchymal transition (EMT) and elicit non-cell autonomous mechanisms of resistance. In this review, we summarize the role of non-coding RNAs for different mechanisms resulting in drug resistance (e.g., drug transport, drug metabolism, cell cycle regulation, regulation of apoptotic pathways, cancer stem cells, and EMT) in the context of gastrointestinal cancers.

Keywords: anticancer drugs; cancer therapy; gastrointestinal tumor; lncRNA; microRNA; non-coding RNA; resistance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Role of non-coding RNAs for the different reasons that can cause resistance to anticancer drugs in liver cancer. For details about target genes and regulated protein expression by the non-coding RNAs, see text.
Figure 2
Figure 2
Role of non-coding RNAs for the different reasons that can cause resistance to anticancer drugs in esophageal cancer. For details about target genes and regulated protein expression by the non-coding RNAs, see text.
Figure 3
Figure 3
Role of non-coding RNAs for the different reasons that can cause resistance to anticancer drugs in gastric cancer. For details about target genes and regulated protein expression by the non-coding RNAs, see text.
Figure 4
Figure 4
Role of non-coding RNAs for the different reasons that can cause resistance to anticancer drugs in colon and colorectal cancer. For details about target genes and regulated protein expression by the non-coding RNAs, see text.
Figure 5
Figure 5
Role of non-coding RNAs for the different reasons that can cause resistance to anticancer drugs in pancreatic cancer. For details about target genes and regulated protein expression by the non-coding RNAs, see text.
Figure 6
Figure 6
Role of non-coding RNAs for the different reasons that can cause resistance to anticancer drugs in gastrointestinal stromal cancer. For details about target genes and regulated protein expression by the non-coding RNAs, see text.
Figure 7
Figure 7
Role of non-coding RNAs for the different reasons that can cause resistance to anticancer drugs in cholangiocarcinoma. For details about target genes and regulated protein expression by the non-coding RNAs, see text.
See this image and copyright information in PMC

References

    1. Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench (2015) 8:19–27. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin (2015) 65:5–29. 10.3322/caac.21254 - DOI - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin (2015) 65:87–108. 10.3322/caac.21262 - DOI - PubMed
    1. Hung AY, Canning CA, Patel KM, Holland JM, Kachnic LA. Radiation therapy for gastrointestinal cancer. Hematol Oncol Clin North Am (2006) 20:287–320. 10.1016/j.hoc.2006.01.016 - DOI - PubMed
    1. Chan BA, Jang RW, Wong RK, Swallow CJ, Darling GE, Elimova E. Improving outcomes in resectable gastric cancer: a review of current and future strategies. Oncology (Williston Park) (2016) 30:635–45. - PubMed

LinkOut - more resources